

Current Listing of Claims:

This listing of claims, with markings to show any changes made, will replace all prior versions, and listings, of claims in the application.

Claims 1-24, 26-29, 31-44 and 49-56 (Canceled)

25. (Original) A method for treating or preventing a disorder alleviated by inhibiting dopamine reuptake, wherein the disorder is an addictive disorder, comprising administering to a patient in need of such treatment or prevention an effective amount of (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, each being substantially free of its corresponding (+)-enantiomer.

30. (Currently Amended) The method for treating or preventing a disorder alleviated by inhibiting dopamine reuptake according to claim 25, wherein the addictive disorder is selected from the group consisting of eating disorders, impulse control disorders, alcohol-related disorders, nicotine-related disorders, amphetamine-related disorders, cannabis-related disorders, cocaine-related disorders, hallucinogen-use disorders, inhalant-related disorders, and opioid-related disorders.

45. (Currently Amended) A method for treating or preventing an addictive disorder alleviated by inhibiting dopamine reuptake, comprising administering to a patient in need of such treatment or prevention an effective amount of (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, each being substantially free of its corresponding (+)-enantiomer.

46. (Currently Amended) The method for treating or preventing an addictive disorder alleviated by inhibiting dopamine reuptake according to claim 45, wherein the (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than about 2% w/w of the corresponding (+)-enantiomer.

47. (Currently Amended) The method for treating or preventing an addictive disorder alleviated by inhibiting dopamine reuptake according to claim 45, wherein the (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than about 1% w/w of the corresponding (+)-enantiomer.

48. (Currently Amended) The method for treating or preventing an addictive disorder alleviated by inhibiting dopamine reuptake according to claim 45, wherein the addictive disorder is selected from the group consisting of eating disorders, impulse control disorders, alcohol related disorders, nicotine-related disorders, amphetamine-related disorders, cannabis-related disorders, cocaine-related disorders, hallucinogen-use disorders, inhalant-related disorders, and opioid-related disorders.